August 13, 2009 - First Hospital in the U.K. Implements ZOLL AutoPulse

INVESTOR CONTACT:

A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

FIRST HOSPITAL IN THE U.K. IMPLEMENTS ZOLL AUTOPULSE
IN THE CATH LAB

Basingstoke and North Hampshire NHS Foundation Trust Values AutoPulse for Effective, Continuous CPR

August 13, 2009 ─ CHELMSFORD, MASS. – ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that Basingstoke and North Hampshire Hospital in Hampshire, U.K. is the first hospital to install the AutoPulse® Non-Invasive Cardiac Support Pump in the cardiac catheterization laboratory in the U.K.

“Providing high-quality CPR in a cath lab is challenging, especially without proper positioning due to the way a cath lab table is built on a pedestal base. Providing chest compressions during interventional catheterization can expose staff to significant radiation,” said Carl Brookes, M.D., Consultant Cardiologist for Basingstoke and North Hampshire. “Using the AutoPulse solves the challenge staff face in providing CPR while the cath lab table is off its pedestal base, which can cause damage to the table and subsequently endanger the patient.”

“Moreover, with our new process of ensuring primary angioplasty service 24/7 and fitting stents into a patient’s heart within minutes of their arriving at the hospital, we are seeing higher risk patients arriving in the cath lab. The AutoPulse can provide consistent, uninterrupted chest compressions that may be more effective than manual CPR and more importantly, we can continue to screen while actively compressing,” Dr. Brookes added. “Internationally, there are increasing reports of good outcomes in patients whose interventional procedure was performed during CPR. Plus, people get fatigued doing CPR. The AutoPulse gives us one less thing to worry about.”

“Basingstoke and North Hampshire’s installation of the AutoPulse to provide circulatory support during catheterizations will, we hope, be a key component of improving patient outcomes from sudden cardiac arrest and provide a good model for other NHS Foundation hospitals,” said Jonathan A. Rennert, President of ZOLL.  “We’re seeing more and more hospitals, both large and small, interested in AutoPulse for their cath labs.”

The AutoPulse Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse may offer a significant advantage over manual CPR, moving blood more consistently than human providers. AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.

Over 4,200 AutoPulse devices are in use in hospital and emergency service organizations worldwide.

About Sudden Cardiac Arrest

SCA, an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs, claims more than 1 million lives each year. It is the leading cause of unexpected death in the world and strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA.

About Basingstoke and North Hampshire NHS Foundation Trust (BNHFT)

Basingstoke and North Hampshire NHS Foundation Trust (BNHFT) provides acute hospital services to a population of around 300,000 patients in Hampshire and Berkshire. It has the highest rating from the Healthcare Commission and is one of only 12 NHS Trusts to achieve double excellent two years running. 

The majority of services are provided from Basingstoke and North Hampshire Hospital, which has around 450 beds, employs 2,800 staff, and treats over 250,000 patients annually. In 1999, it became the first hospital in Europe to perform surgery using equipment operated by voice commands. Basingstoke, which is located about an hour southwest of London, is an economic center and serves as the U.K. and international headquarters for many well-known corporations.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company’s resuscitation product development. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, LifeBand, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.